Shattuck Labs Inc (NAS:STTK)
$ 7.24 -0.09 (-1.23%) Market Cap: 344.27 Mil Enterprise Value: 236.98 Mil PE Ratio: 0 PB Ratio: 2.67 GF Score: 66/100

Shattuck Labs Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Nov 29, 2022 / 06:00PM GMT
Release Date Price: $2.18 (-0.46%)
Jonathan Miller
Evercore ISI - Analyst

Good afternoon everybody. Welcome to our fireside with Shattuck. Thanks, Taylor, for joining us. We're very excited to get into the nitty-gritty here, but why don't I start by Taylor giving you an opportunity to intro the platform a little bit. Can you tell us a little bit about your ARCs and your approach to immunostimulation?

Taylor Schreiber
Shattuck Labs, Inc. - CEO & Co-founder

Sure. Hi Jon, Hi Eric, thanks for the invitation. So the agonist redirected checkpoint or ARC platform is a two-sided Fc-fusion protein platform where one end of these molecules is aimed at blocking different immune checkpoints and the other end is aimed at activating co-stimulatory receptors in the TNF superfamily.

To do that well, these molecules need to -- any TNF receptor agonist really needs to attain at least a trimeric, but even better if it's a hexameric configuration. That's something that we've learned through over 20 years of Phase 1 trials with monoclonal antibodies going after targets like CD40 that just have not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot